Cargando…
非小细胞肺癌脑转移患者接受一代表皮生长因子受体酪氨酸激酶抑制剂治疗的临床研究
BACKGROUND AND OBJECTIVE: A survival analysis and the influencing factors for non-small cell lung cancer (NSCLC) patients with brain metastases accepting first-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKIs) treatment have not yet been elucidated to date. In this st...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5972976/ https://www.ncbi.nlm.nih.gov/pubmed/28228223 http://dx.doi.org/10.3779/j.issn.1009-3419.2017.02.06 |
Ejemplares similares
-
表皮生长因子受体酪氨酸激酶抑制剂在晚期非小细胞肺癌一线治疗中的应用
Publicado: (2010) -
表皮生长因子酪氨酸激酶抑制剂一线治疗突变阳性晚期非小细胞肺癌的临床疗效预测因素分析
Publicado: (2019) -
表皮生长因子受体突变细胞系H1650耐药机制探讨
Publicado: (2012) -
抗表皮生长因子受体和抗血管内皮生长因子药物在非小细胞肺癌治疗中的作用
por: LANGER, Corey, et al.
Publicado: (2010) -
酪氨酸激酶抑制剂耐药机制及其治疗策略
Publicado: (2011)